MYC dysregulation, including MYC gene rearrangement and Myc protein overexpression, is of increasing clinical importance in diffuse large B-cell lymphoma (DLBCL). However, the roles of MYC and the relative importance of rearrangement vs overexpression remain to be refined. Gaining knowledge about the tumor biology associated with MYC dysregulation is important to understand the roles of MYC and MYC-associated biology in lymphomagenesis. In this study, we determined MYC rearrangement status (n = 344) and Myc expression (n = 535) in a well-characterized DLBCL cohort, individually assessed the clinical and pathobiological features of patients with MYC rearrangement and Myc protein overexpression, and analyzed the prognosis and gene expression profiling signatures associated with these MYC abnormalities in germinal center B-cell-like and activated B-cell-like DLBCL. Our results showed that the prognostic importance of MYC rearrangement vs Myc overexpression is significantly different in germinal center B-cell-like vs activated B-cell-like DLBCL. In germinal center B-cell-like DLBCL, MYC-rearranged germinal center B-cell-like DLBCL patients with Myc overexpression significantly contributed to the clinical, biological, and prognostic characteristics of the overall
Myc-overexpressing germinal center B-cell-like DLBCL group. In contrast, in activated B-cell-like DLBCL, the occurrence, clinical and biological features, and prognosis of Myc overexpression were independent of MYC rearrangement. High Myc levels and Myc-independent mechanisms, either tumor cell intrinsic or related to tumor microenvironment, conferred significantly worse survival to MYC-rearranged germinal center B-cell-like DLBCL patients, even among Myc high Bcl-2 high DLBCL patients. This study provides new insight into the tumor biology and prognostic effects associated with MYC dysregulation and suggest that detection of both MYC translocations and evaluation of Myc and Bcl-2 expression is necessary to predict the prognosis of DLBCL patients. Modern Pathology (2015) 28, 1555-1573; doi:10.1038/modpathol.2015.118; published online 6 November 2015 MYC is a proto-oncogene that encodes the Myc protein, which is critical for cell proliferation, growth, metabolism, differentiation, apoptosis, and immune responses. In mouse models, Myc inactivation induces sustained tumor regression via both tumor cellintrinsic and host-dependent mechanisms. 1 The selective small-molecule bromodomain inhibitor JQ1 has a potent antiproliferative effect that was associated with the effective downregulation of MYC and Myc target genes 2 rendering this agent to have great therapeutic potential. 3 The chromosomal rearrangement or translocation involving MYC and other genes (most commonly the immunoglobulin heavy-chain gene (IGH) locus) leads to Myc overexpression and occurs in~10% of diffuse large B-cell lymphomas (DLBCLs). [4] [5] [6] [7] [8] DLBCL is the most common type of non-Hodgkin's lymphoma, and among MYC-rearranged aggressive lymphomas, DLBCL is the entity that clinicians most commonly encounter. 9, 10 Several studies have reported that MYC translocations independently predicted significantly poor survival in DLBCL patients. [11] [12] [13] [14] [15] [16] However, other studies found inconsistent results [17] [18] [19] or limitations of its prognostic significance. 20, 21 The clinical significance of Myc overexpression in DLBCL has also been the source of much attention and controversy. Several groups including ours have found that DLBCL with high Myc protein expression detected by immunohistochemistry had inferior survival. 5, 13, [22] [23] [24] Furthermore, the poor prognosis associated with Myc overexpression was contributed by cases with Myc/Bcl-2 coexpression-'doublepositive lymphoma' (DPL)-which account for 18-44% of DLBCLs. 13, 20, [23] [24] [25] [26] However, one study showed that the prognostic value of double-positive lymphoma was lost in younger DLBCL patients with poor prognosis. 27 Inconsistent results have been reported regarding whether the prognostic significance of Myc or Myc/Bcl2 protein expression depends on MYC or MYC/BCL2 gene rearrangement status or not. 8, 13, 20 Other issues include whether Myc/Bcl2 immunohistochemistry is robust and reproducible, 28 and that immunohistochemistry cutoff values have varied among different study groups, 13, 20, [23] [24] [25] [26] which may affect the specificity of this combined biomarker for poorer prognosis.
Possible molecular mechanisms underlying the inconsistent clinical results may include presence or absence of other genetic abnormalities and oncogenic pathways, [29] [30] [31] as well as another aspect of Myc function: promoting apoptosis. 32 Moreover, researchers have recently reported findings that Myc is a universal amplifier of 10-15% in human genome, suggesting that Myc function is nonspecific and that the consequences of MYC activities are affected by pre-existing molecular programs in the tumor cells. 33, 34 Therefore, tumor biology associated with MYC/Myc (designated MYC herein) abnormalities may have important roles in the observed adverse prognosis.
Taken together, both MYC gene rearrangement and Myc protein overexpression have been correlated with significantly adverse prognosis in DLBCL. However, how much of these two biomarkers overlap and differ, how much their associated tumor biology affects the prognostic effects, and whether the MYC functional role is molecular contextdependent are not very clear. In this study, we compared the occurrence and clinicopathologic features of patients stratified by MYC rearrangement and Myc expression status, and analyzed the differential prognosis and gene expression profiling associated with these MYC abnormalities in a wellcharacterized DLBCL cohort to assess the utility of these two genetic and protein biomarkers and explore the prognostic determinants. This study is important for achieving the goal of precision medicine in DLBCL.
Patients and methods

Patients
The study cohort consisted of 539 R-CHOP-treated patients with de novo DLBCL from the International DLBCL Rituximab-CHOP Consortium Program, including 466 cases from the training set of a previous study, 24 and additional 73 cases with either Myc immunohistochemistry or MYC gene rearrangement status determined. The diagnostic criteria, review process, and eligibility and exclusion criteria have been described previously. 35, 36 The cell-oforigin classification as either the germinal center B-cell-like (GCB) or activated B-cell-like (ABC) subtype was determined using gene expression profiling and/or immunohistochemistry for CD10, BCL6, GCET-1, FOXP1, and MUM1 using the ViscoYoung and/or Choi algorithms as described previously. 24, 35, 36 Totally, 276 cases were classified as GCB, 259 cases were classified as ABC, and 4 cases were unclassifiable. All patients underwent standard R-CHOP or R-CHOP-like therapy, and the median follow-up time was 45 months (range, 30-176.1 months). This study was conducted in accordance with the Declaration of Helsinki and was approved as being of minimal to no risk or as exempt by the institutional review boards of all participating centers, including The University of Texas MD Anderson Cancer Center.
Fluorescence In Situ Hybridization, Immunohistochemistry, and Gene Sequencing MYC translocation was detected by fluorescence in situ hybridization using two probes (a locusspecific identifier IGH/MYC/CEP8 tri-color dualfusion probe and a locus-specific identifier MYC dual-color break-apart probe) (n = 344). Myc expression was assessed by immunohistochemistry using tissue microarray sections and a monoclonal anti-(c) MYC antibody, clone Y69 (Epitomics, Burlingame, CA, USA) (n = 535). The experimental techniques and scoring processes have been described previously. 15, 21, 24 Evaluation of other biomarker expression by immunohistochemistry was also performed on tissue microarray sections using corresponding antibodies: p53 (DO-7; Dako, Carpinteria, CA, USA), MDM2 (IF2; Calbiochem, Billerica, MA, USA), Bcl-2 (Clone-124; Dako), Ki-67 (MIB-1; Dako), pAKT (726E11; CST), Bcl-6 (PG-B6p; DAKO), FOXP1 (EPR4113; Abcam), MUM1/IRF4 (Dako), CD10 (56C6; Vantana), CD30 (clone BerH2; Dako), BLIMP-1 (EPR16655; Epitomics), NF-κB subunits (Dako), CXCR4 (Abcam, Cambridge, MA, USA), and survivin (EP2880Y; Epitomics). BCL6 and BCL2 translocations and TP53 mutations were detected as described previously. 15, 21, 24, [35] [36] [37] [38] [39] [40] [41] [42] Gene Expression Profiling Gene expression profiling for 457 patients was performed using the Affymetrix GeneChip Human Genome HG-U133 Plus 2.0 Array as described previously. 21, 24, [35] [36] [37] The CEL files have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus repository (GSE31312). Microarray data were normalized for further supervised clustering analysis. Multiple t-tests were used to identify differentially expressed genes and the P-values obtained were corrected for the false discovery rate using the β-uniform mixture method.
Statistical Analysis
The clinical and pathobiological features of DLBCL patients at the time of presentation were compared using the χ 2 test. The mean expression levels of biomarkers between DLBCL groups with or without MYC abnormalities were also compared by unpaired t-test. Overall survival (OS) was calculated from the time of diagnosis to last follow-up or death from any cause. Progression-free survival (PFS) was calculated from the time of diagnosis to disease progression, disease relapse, or death from any cause. Patients who were alive and disease progression-free at last follow-up were censored. Survival analysis was performed using the Kaplan-Meier method with the Prism 5 program (GraphPad Software, San Diego, CA, USA), and differences in survival were compared using the log-rank (Mantel-Cox) test. Multivariate survival analysis was performed using a Cox proportional hazards regression model with the SPSS software program (version 19.0; IBM Corporation, Armonk, NY, USA). All differences with P ≤ 0.05 were considered statistically significant.
Results
Myc Expression in Germinal Center B-Cell-Like and Activated-B-Cell-Like Subtypes of DLBCL
We observed variable levels of nuclear Myc expression in DLBCL (n = 535) (Figures 1a-c) . The mean expression level of Myc in ABC-DLBCL was significantly higher compared with that in GCB-DLBCL (Figure 1d) . Among the cases successfully tested for MYC rearrangement status (n = 344), 27 (16.3%) of 166 GCB-DLBCL cases and 13 (7.3%) of 177 ABC-DLBCL cases had MYC rearrangement/translocation. Most but not all MYC-rearranged cases (MYC-R + ) had high MYC-mRNA and Myc expression, with an average percentage of Myc high nuclei in the tumor samples of 70.5% (Supplementary Figure S1A) . We thus set the cutoff for Myc overexpression (Myc high ) at ≥ 70%, so that Myc expression levels in MYCnon-rearranged (MYC-R − ) Myc high patients comparably 'matched' those in MYC-R + /Myc high cases (Supplementary Figure S1C) (Figures 2a and b) . Nineteen (73%) of the 26 MYC-R + GCB patients (one MYC-R + GCB case had no expression data available) and 7 (54%) of the 13 MYC-R + ABC patients were Myc high , who had significantly higher MYC transcripts and significantly worse survival compared with the MYC-R + /Myc low cases (Figures 1e-g and Supplementary Figures S1D). Compared with MYC-R − patients, MYC-R + /Myc high patients had significantly worse survival in GCB-DLBCL (P = 0.0001 for OS and P o 0.0001 for PFS) but not in ABC-DLBCL (P = 0.56 for OS and P = 0.14 for PFS) ( Supplementary  Figures S1E and F) . Comparison of MYC expression levels between the MYC-R + GCB, MYC-R − GCB, MYC-R + ABC, and MYC-R − ABC Myc high groups revealed that MYC-R + /Myc high GCB-DLBCL had significantly higher Myc protein expression levels compared with all other subsets, and that among both the GCB and ABC subtypes, MYC-R + /Myc high cases had a significantly higher level of MYC-mRNA levels compared with MYC-R − /Myc high cases (Figures 2c and d) .
Clinical Parameters Associated with Myc Overexpression and MYC Rearrangement
We analyzed the clinical parameters associated with Myc overexpression ( (Table 1) . Similarly, in GCB-DLBCL, MYC-R + patients were enriched in patients with adverse clinical features, whereas in ABC-DLBCL, MYC rearrangement was only associated with primary extranodal origin. The GCB subtype compared with the ABC subtype of MYC-R + patients showed trends toward having a higher proportion of patients with bone marrow involvement and non-complete treatment response (Supplementary Table S1 ).
In both the GCB-and ABC-DLBCL groups, MYC-R + /Myc high patients appeared to have similar clinical features with MYC-R − /Myc high patients (except complete response rate), yet may have elevated serum lactate dehydrogenase levels and higher frequency of extranodal origin (Supplementary Table S2 ). 
Molecular Biomarkers Associated with Myc Overexpression and MYC Rearrangement
Myc high DLBCL compared with Myc low DLBCL, in addition to having higher Myc levels and significantly higher frequencies of MYC translocation and ABC subtype (Table 1) , had higher expression levels of p53, MDM2, Bcl-2 (Myc high ABC-DLBCL only), Bcl-6, FOXP1, IRF4/MUM1 (Myc high ABC-DLBCL only), Ki-67, pAKT, CXCR4, and CD10 (Myc high GCB-DLBCL only), but lower expression levels of BLIMP-1 (in ABC-DLBCL only) and nuclear expression of the NF-κB subunits c-Rel and RelB (in ABC-DLBCL only, P = 0.019, figure not shown) (Figure 3) . At the mRNA level, only MDM2 (in GCB-DLBCL only), FOXP1 (in ABC-DLBCL only), IRF4 (in ABC-DLBCL only), and MME/CD10 transcript levels showed corresponding correlations consistent with those at the protein level (Figures 4a-d) . PRDM1 mRNA levels were significantly lower in Myc high GCB-DLBCL compared with that in Myc low GCB-DLBCL (P = 0.0005). The GCB and ABC subtypes of Myc high patients differed in frequencies of MYC translocation, BCL2 translocation, TP53 mutation (all higher in the GCB subtype), and expression levels of Bcl-2, p50, c-Rel (all higher in the ABC subtype), pAKT (higher in the GCB subtype), and cell-oforigin-related biomarkers (Bcl-6, BLIMP-1, GCET-1, CD10, FOXP1, MUM1) (Table 1, Figure 3 , and Supplementary Table S3 ). Some of the pathobiological associations with Myc high DLBCL were shared by MYC-R + GCB-DLBCL patients (compared with MYC-R − GCB-DLBCL; Supplementary Tables S1 and S3). On the other hand, in addition to the difference in Myc activation mechanisms (MYC translocation or not), MYC-R + /Myc high compared with MYC-R − /Myc high patients had higher frequencies of GCB subtype and BCL2 translocation, and lower frequencies of BCL6 translocation, MUM1, CD30, and p52 expression (Supplementary Table S2 and S3). Among GCB-DLBCL patients, MYC-R + /Myc high compared with MYC-R − /Myc high patients had significantly higher expression levels of MDM2, CD10, and FOXP1 but a lower expression level of CD30; among ABC-DLBCL patients, MYC-R + /Myc high compared with MYC-R − / Myc high was associated with lower expression levels of Bcl-6 and pAKT (Figures 4f-l) . 
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Prognostic Effect of Myc Overexpression with or without MYC Translocations and Associated Gene Expression Profiling Signatures
We combined the survival analysis with gene expression profiling comparisons to assess the role of MYC abnormalities in DLBCL and to study potential mechanisms. As in earlier studies, 13, [22] [23] [24] in the present study, high expression levels of Myc was associated with significantly worse OS and PFS in both GCB-and ABC-DLBCL (Supplementary Figure S2) . Similar prognostic impact was also shown by high MYC-mRNA levels in GCB-and ABC-DLBCL (Supplementary Figures S3A-D) . Gene expression profiling analysis showed that Myc high GCB-and ABC-DLBCL had different gene expression profiling signatures ( In the GCB-DLBCL group, MYC-R + /Myc high patients had significantly worse survival than both Myc low and MYC-R − /Myc high patients did. Although MYC-R − /Myc high GCB-DLBCL showed trends towards worse survival compared with the overall Myc low GCB-DLBCL (P = 0.40 for OS, Figure 5a ; P = 0.48 for PFS; Supplementary Figure S4A) , and the MYC-R − /Myc low GCB-DLBCL (for OS: P = 0.32; Supplementary Figure S4C ; for PFS: P = 0.21), the differences were not significant. Biologically, only MYC-R + /Myc high (but not MYC-R − /Myc high ) GCB-DLBCL compared with Myc low GCB-DLBCL showed a distinct gene expression profiling signature (false discovery rate o 0.01) (Figure 5b , Supplementary Table S4B, and Table 3) , and this signature mostly overlapped the Myc high gene expression profiling signature identified in the overall GCB-DLBCL group (Table 2 and Supplementary Figure S2D ) involving cell proliferation, gene expression, metabolism, apoptosis, microenvironment and immune response, and microRNA genes. In contrast, the MYC-R − /Myc high GCB-DLBCL patients compared with Myc low GCB-DLBCL (Supplementary Figures  S4D, Table 3, and Supplementary Table S4B) or MYC-R + /Myc high GCB-DLBCL (Figure 5c , Table 3,   and Supplementary Table S4B) only showed a few differentially expressed genes below false discovery rate threshold of 0.30 (not including MYC), most of which are involved in cell proliferation, gene expression, ribosome biogenesis, and metabolism, suggesting the presence of heterogeneity and posttranscriptional regulation of MYC as a cause of Myc overexpression within the MYC-R − /Myc high GCB-DLBCL group. The comparison between MYC-R + GCB-DLBCL and MYC-R − GCB-DLBCL overall is shown in Supplementary Figure S4E .
In contrast, in ABC-DLBCL, the prognostic significance (Figure 5d ) and gene expression profiling features of Myc overexpression did not depend on MYC translocation. MYC-R − /Myc high ABC-DLBCL had significantly poorer survival compared with the overall Myc low or MYC-R − /Myc low ABC-DLBCL (Figure 5d and Supplementary Figures S4G-I ) and distinct gene expression profiling signatures (false discovery rate o 0.01; Figure 5e and Supplementary Table S4C ). The genes in the MYC-R − /Myc high ABC-DLBCL gene expression profiling signature, overlapped with differentially expressed genes between the overall Myc high vs Myc low ABC-DLBCL patients, included typical Myc targets mainly related to cell proliferation, the cell cycle, gene expression, ribosome biogenesis, metabolism (Table 4) (Figure 5f ) (between MYC-R + /Myc high and MYC-R + /Myc low GCB-DLBCL, or between MYC-R + /Myc high and MYC-R + /Myc low ABC-DLBCL, we did not find significant differentially expressed genes below false discovery rate thresholds of 0.05-0.50). MYC-R + ABC-DLBCL appears to have decreased B-cell receptor signaling compared with MYC-R + GCB-DLBCL (false discovery rate o 0.30; Table 4 and Supplementary  Table S4C ). However, the 'loss' of the gene expression profiling signature may also be due to the small case number.
Comparing between GCB and ABC subtypes of Myc high patients, the overall GCB and ABC subtypes of Myc high patients showed no significant difference in survival (ABC subtype showed nonsignificant trends towards poorer survival; Supplementary  Figures S3E and F) . However, MYC-R + /Myc high GCB-DLBCL showed unfavorable trends compared with Myc high ABC-DLBCL (either MYC-R − or MYC-R + ). The P-value for the difference in PFS between the MYC-R + /Myc high GCB-DLBCL and MYC-R − /Myc high ABC-DLBCL patients was 0.058 ( Figure 5g (Table 5 and Supplementary Table  S4D ). These analyses suggest the distinctive biology of MYC-R + /Myc high GCB-DLBCL and cell of origin during lymphomagenesis may have a role in defining its biological feature.
Concurrent Evaluation of Myc/Bcl-2 Overexpression and MYC Translocations
We examined whether the prognostic value of Myc overexpression is contributed by or depends on the molecular marker associations with Myc high DLBCL as shown in Figure 3 . As shown previously, the prognostic significance of Myc high and Bcl-2 high in DLBCL significantly depend on each other. 13, 20, [23] [24] [25] [26] In addition, to a certain extent, the prognostic significance of Myc high showed dependence on CXCR4, 40 FOXP1, and MUM1 overexpression, which are also associated with Bcl-2 overexpression (the association of MUM1 was only in ABC but not in GCB), high Ki-67 (for OS but not for PFS), and low BLIMP-1 expression (Supplementary Figure S5) . The lack of prognostic significance of Myc overexpression without MYC translocation in GCB-DLBCL (Figure 5a ) could be attributable to the favorable prognosis of Myc high /Bcl-2 low GCB-DLBCL patients (Figures 6a and b and Supplementary Figures S6A and B) . In contrast, in the ABC-DLBCL group, most MYC-R − /Myc high patients (64%) also had Bcl-2 overexpression, which contributed to this group's worse survival. Concurrent Bcl-2 overexpression also had significant prognostic impact in MYC-R + /Myc high GCB-DLBCL (Figures 6c  and d ), but not in overall MYC-R + ABC-DLBCL, Figures S6C and D) ; however, we could not distinguish whether the synergy in GCB is with Bcl-2 protein or with BCL2 translocation. Compared with Myc low , MYC-R − /Myc high GCB-DLBCL, or overall MYC-R − GCB-DLBCL, MYC-R + / Myc high GCB-DLBCL showed nonsignificant trends toward higher Bcl-2 levels (P = 0.34, 0.27, and P = 0.17, respectively; figures not shown; Supplementary Tables S1 and 2 ). The gene expression profiling analysis revealed no significant differentially expressed genes between MYC-R + GCB-DLBCL with Bcl-2 expression and MYC-R + GCB-DLBCL without Bcl-2 expression. Correspondingly, patients with MYC/BCL2 double-hit lymphoma and those with single MYC rearrangements did not have significant differentially expressed genes, which is consistent with an earlier study. 16 The survival of MYC-R + Myc high /Bcl-2 high GCB-DLBCL patients was markedly poorer compared with that of MYC-R − Myc high /Bcl-2 high GCB-DLBCL patients but this difference was not significant (Figures 6e and f) . However, this difference was significant when we used cutoffs of ≥ 40% or 450% for Myc overexpression.
MYC-R + /Myc high ABC-DLBCL, or MYC-R + /Myc low cases (Supplementary
Although concurrent evaluation of Myc and Bcl-2 expression improves the specificity of Myc biomarker in DLBCL, MYC rearrangement continues to demonstrate clinical value. In our cohort, there was no significant difference in survival between patients with the GCB or ABC subtypes of MYC-R − Myc high / Bcl-2 high (ie, double-positive lymphoma). Among overall double-positive lymphoma patients, patients with MYC-R + GCB double-positive lymphoma patients had significantly poorer survival compared with those double-positive lymphoma patients without MYC rearrangement (Figures 6g and h) . The survival of MYC-R + double-positive lymphoma patients with the GCB or ABC subtypes appeared to be different, although P-values were not significant and the case numbers were small.
Discussion
Previously, we reported MYC translocation and Myc overexpression as adverse prognostic biomarkers individually. 15, 24 In this study, we analyzed the occurrence of MYC translocation and Myc overexpression in GCB-and ABC-DLBCL (Figures 2a and  b) , and compared with the clinical features and tumor biology associated with these two overlapping biomarkers which have not been done by previous studies, and examined the dependence/independence between their indicated prognoses. To reduce the difference in Myc expression levels as a causing factor for the differential prognostic effect and tumor biology between MYC translocation and Myc overexpression activated by other mechanisms, the cutoff for Myc high was set at ≥ 70% in this study, which is the optimal cutoff for predicting MYC translocation according to previous studies. 6, 7, 31 Using this cutoff, the frequency MYC-associated biology and prognosis in DLBCL of Myc overexpression was 32.7% in overall DLBCL patients (close to the frequencies by other independent studies 13, 22, 23 ), 73% in MYC-R + GCB-DLBCL, and 54% in MYC-R + ABC-DLBCL (lower than the 93% in Green et al 6 and 85% in Horn et al 10 ). Tables 6-7 summarize the results of published MYC studies including ours. The current study shows that MYC translocation and Myc overexpression in DLBCL only partially overlaps and evaluation of both is critical for stratifying patients and predicting treatment outcomes. MYC-rearranged DLBCL without Myc protein overexpression did not show significantly worse survival (Figure 1g ). However, evaluation of Myc overexpression alone is also insufficient for Among patients with MYC-R + /Myc high GCB-DLBCL, those with Bcl-2 overexpression had significantly poorer progression-free survival compared with those who did not have Bcl-2 overexpression. The P-value for overall survival was not significant. (e and f) Among patients with Myc high Bcl-2 high GCB-DLBCL, those with MYC rearrangement had poorer overall and progression-free survival compared with those without MYC rearrangement did, but these differences were not statistically significant. (g and h) Among Myc high Bcl-2 high DLBCL patients, GCB-DLBCL patients with MYC rearrangement had significantly poorer overall and progression-free survival than Myc high Bcl-2 high patients without MYC rearrangement did. ABC, activated-B-cell-like; Bcl-2 high, high Bcl-2 protein expression; Bcl-2 low , low Bcl-2 protein expression; GCB, germinal-center-B-cell-like; Myc high , high Myc protein expression; MYC-R + , MYC rearrangement-positive; MYC-R − , MYC rearrangement-negative.
predicting poorer prognosis in MYC-R − cases, especially in MYC-R − GCB-DLBCL (Figure 5a ). This low specificity for Myc high as an adverse prognostic factor can be improved by concurrent evaluation of Bcl-2 expression (Supplementary Figures S5 and S6) , which is overexpressed mainly in ABC-DLBCL and associated with Myc overexpression. However, the survival of MYC-rearranged Myc high Bcl-2 high GCB double-positive lymphoma patients remains significantly worse than other double-positive lymphoma patients (Figures 6g and h) . The biological investigation (in this regard, ≥ 70% is a better cutoff compared with ≥ 40% for Myc high in our cohort) revealed that MYC activation was associated with significantly increased or decreased expression of genes and proteins involved in cell proliferation (e.g., pAKT, Ki-67), apoptosis (p53, Bcl-2, FAS, BCL2A1, PEG10, HINT1, TRAF1), differentiation (PRDM1, BLIMP-1, BACH2 (which represses PRDM1) 43 ), noncoding RNAs (eg, LINC00152, GAS5, SNHG1, NAPSB) and microRNAs, microenvironment, and immune responses, as well as cellof-origin markers ( Figure 3 and Tables 3-5 Figures S4D and F) . Remarkably, MYC-R + / Myc high GCB-DLBCL had a characteristic gene expression profiling in DLBCL. Myc activation was associated with gene expression profiling signatures suggesting decreased immune responses and a number of microRNAs overlapped with the molecular Burkitt lymphoma signature, 29, 30 including MIR17HG, which was markedly upregulated, and MIR21 (ref. 44 ) and MIR155HG, which were significantly downregulated. Other studies have shown these microRNAs to be regulated by the Myc, Bcl-6, STAT3, and NF-κB pathways, and the MIR17HG locus was frequently amplified in Burkitt lymphoma. [45] [46] [47] [48] Downregulation of MIR155HG expression may contribute to the pathogenesis of MYC translocation, as miR-155 suppresses activation-induced cytidine deaminase, which mediates MYC/IGH translocation. 49 These microRNA signatures may also be implicated in defining the gene expression profiling features of MYC-R + /Myc high GCB-DLBCL. In lymphoma cells, ectopic expression of miR-155 is associated with downregulation of IGJ, FAS, SMAD3/5, and BACH1, as well as HLA genes. 45 IGJ, FAS, and genes involved in BMP/SMAD pathways (such as SMAD1, BMP3, and BMP7), as well as SMARCA4 (miR-21 target gene 50 ), were upregulated in MYC-R + GCB-DLBCL (Tables 3 and 5) . miR-155 target gene BCL2 showed increased Bcl-2 protein expression in ABC-DLBCL (Figure 3c ). Phosphorylated SMAD proteins have roles in BMP-induced cell growth inhibition (this inhibition can be overcame via MYC translocations), 51, 52 immunoregulation, 53 and ionizing radiation-induced double-strand break signaling. 54 In addition, in MYC-R + /Myc high GCB-DLBCL, antiapoptotic PEG10 and ZNF385B, which modulates p53 activity resulting in cell-cycle arrest over apoptosis, were significantly upregulated.
One possible reason for the differential prognoses and gene expression profiling signatures among GCB or ABC subtype of Myc high and MYC-R + cases is the difference in Myc protein levels. For example, MYC-R + /Myc high GCB-DLBCL had highest Myc expression levels ( Figure 2c ) and significant or nonsignificant trends towards worse prognosis compared with all other three Myc high groups. MYC-R + cases with low Myc protein expression had good prognosis even though having an MYC rearrangement. Different MYC translocation partners, and/or breakpoints outside of MYC gene leaving MYC repressor element intact during rearrangement, 4,17 may cause the low MYC-mRNAs in these MYC-R + /Myc low DLBCL cases (Figures 1e-g ). Compared with MYC-R + /Myc high GCB-DLBCL, ABC subtype of MYC-R + /Myc high DLBCL had similar MYC-mRNA but significantly lower Myc protein levels ( Figure 2d ) and trends of better survival. MYC-R − /Myc high GCB-DLBCL compared with Myc low GCB-DLBCL had significantly higher levels of MYC-mRNA and Myc protein, but the false discovery rate for MYC upregulation in gene expression profiling analysis was high (40.45), which may suggest either Myc high or Myc low group are heterogeneous and the molecular mechanisms inducing Myc in this Myc high group include post-transcriptional regulation. A previous Myc study in immature and mature GCB cells during germinal cell formation also demonstrated the lack of correlation between Myc protein and mRNA levels. 55 The lack of distinct gene expression profiling signatures and better survival of MYC-R − /Myc high GCB-DLBCL and MYC-R + /Myc high ABC-DLBCL compared with MYC-R + /Myc high GCB-DLBCL may indicate lower Myc activities corresponding to intracellular Myc protein levels; however, small case numbers and/or heterogeneity among these two Myc high DLBCL groups could also be possible causes.
However, the Myc immunohistochemistry levels were similar between MYC-R − /Myc high GCB-DLBCL and MYC-R − /Myc high ABC-DLBCL (although GCB type had slightly lower level of MYC-mRNA) but their prognosis showed differences. MYC-R + /Myc high ABC-DLBCL had similar Myc protein level to that of MYC-R − /Myc high ABC-DLBCL but only the latter showed typical Myc gene expression profiling signatures (Figure 2c) . Therefore, Myc-associated molecular mechanisms in GCB or ABC subtype of MYC-R +/ − Myc high cases impacted the prognostic and biological effect of Myc. GCB and ABC subtypes of Myc high DLBCL had difference in frequencies of TP53 mutation, MYC translocation, BCL2 translocation, and Bcl-2 expression, as well as cell-of-origin biomarkers (Table 1 and Figure 3) . MYC-R + /Myc high and MYC-R − /Myc high DLBCL had significantly different levels of MDM2, the cell-of-origin markers, and CD30 (in GCB-DLBCL) and pAKT (in ABC-DCLBL) (Figure 4 ), as well as significantly different gene expression profiling signatures at the mRNA level (Figure 5i) . Recently, studies have posited a 'c-Myc function rule,' in which c-Myc is a 'universal amplifier' of active (expressed) genes in lymphocytes. 33, 34, 57 In summary, both MYC rearrangement and Myc overexpression have advantage and limitations as a single biomarker in DLBCL, and their prognostic importance is significantly different in GCB-vs ABC-DLBCL. GCB subtype (opposite to the general association of ABC-DLBCL with poorer survival) of MYC-R + DLBCL with Myc overexpression was associated with significantly poorer survival, likely contributed by significantly higher Myc protein levels as well as associated tumor biology. In ABC-DLBCL, Myc overexpression associated with Bcl-2 overexpression was a significantly adverse biomarker independent of MYC translocation. Our results suggest that fluorescence in situ hybridization analysis for MYC rearrangements and immunohistochemistry evaluation for Myc and Bcl-2 expression are both needed to determine the prognosis in subsets of patients. 57 Insights gained into the tumor biology associated with MYC abnormalities are important for understanding the functional role of MYC in lymphomagenesis and chemoresistance, Occurrence of GCB vs ABC subtype of MYC-R + /Myc high /Bcl-2 high : 2.5 Prognosis of GCB vs ABC subtype of MYC-R + : trends towards poorer OS and PFS (P = 0.11); Prognosis of GCB vs ABC subtype of MYC-R + /Myc high : no significant difference (slightly unfavorable trends); Prognosis of GCB vs ABC subtype of MYC-R + /Myc high /Bcl-2 high : unfavorable trends (for PFS, P = 0.098) Abbreviations: ABC, activated-B-cell like; Bcl-2 high , high Bcl-2 protein expression; DLBCL, diffuse large B-cell lymphoma; DPL, double-positive lymphoma; EFS, event-free survival; GCB, germinal center B-cell like; Myc high , high Myc protein expression; Myc low , low Myc protein expression; MYC-R + , MYC rearrangement positive; MYC-R¯, MYC rearrangement negative; OS, overall survival; PFS, progression-free survival. Note: Case numbers marked by * are the total Myc high or Myc low case numbers (with or without MYC-R status determined).
and help identify oncogenic targets for therapeutic intervention (Table 7) . Abbreviations: ABC, activated B-cell like; Bcl-2 high , high Bcl-2 protein expression; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; GCB, germinal center B-cell like; Myc high , high Myc protein expression; Myc low , low Myc protein expression; MYC-R − , MYC rearrangementnegative; MYC-R + , MYC rearrangement positive; OS, overall survival; PFS, progression-free survival.
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